1. Home
  2. TTEK vs IBRX Comparison

TTEK vs IBRX Comparison

Compare TTEK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tetra Tech Inc.

TTEK

Tetra Tech Inc.

HOLD

Current Price

$27.36

Market Cap

7.9B

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$7.36

Market Cap

7.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTEK
IBRX
Founded
1966
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9B
7.2B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
TTEK
IBRX
Price
$27.36
$7.36
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$44.00
$12.57
AVG Volume (30 Days)
3.3M
12.1M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
0.82%
N/A
EPS Growth
N/A
38.71
EPS
0.76
N/A
Revenue
$2,964,148,000.00
$113,288,000.00
Revenue This Year
N/A
$88.59
Revenue Next Year
$6.43
$131.15
P/E Ratio
$36.08
N/A
Revenue Growth
7.66
668.31
52 Week Low
$25.81
$1.95
52 Week High
$43.14
$12.43

Technical Indicators

Market Signals
Indicator
TTEK
IBRX
Relative Strength Index (RSI) 42.83 50.24
Support Level $26.98 $6.69
Resistance Level $28.68 $8.54
Average True Range (ATR) 1.02 0.39
MACD 0.14 -0.00
Stochastic Oscillator 25.79 81.33

Price Performance

Historical Comparison
TTEK
IBRX

About TTEK Tetra Tech Inc.

Tetra Tech Inc provides consulting and engineering services for environmental, infrastructure, resource management, energy, and international development markets. It specializes in providing water-related services for public and private clients. It designs infrastructure, facilities, and other structures with complex plans and resource management. it has two reportable segments. Its Government Services Group (GSG) segment includes activities with U.S. government clients (federal, state and local) and activities with development agencies world-wide. Commercial/International Services Group (CIG) segment, which derives maximum revenue, includes activities with U.S. commercial clients and international clients other than development agencies.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Share on Social Networks: